Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents

Cancer Treat Rep. 1979 Jan;63(1):137-8.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Alkylating Agents / therapeutic use
  • Altretamine / adverse effects
  • Altretamine / therapeutic use*
  • Clinical Trials as Topic
  • Drug Evaluation
  • Drug Resistance
  • Female
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Triazines / therapeutic use*

Substances

  • Alkylating Agents
  • Triazines
  • Altretamine